Jennifer M Hill, Anne E Tattersfield Chest physicians are all too aware of the serious side effects associated with the long term use of systemic corticosteroids, particularly weight gain, indigestion, impairment of glucose tolerance, and osteoporosis. The introduction of potent and topical inhaled corticosteroids allowed most patients on regular oral corticosteroids to reduce or stop these, but there are still patients with chronic severe asthma whose symptoms are inadequately controlled by high doses of inhaled corticosteroids and maximal bronchodilator therapy. Such patients receive increasingly frequent courses of oral corticosteroids, often culminating in their long term use. Side effects may not be a problem with a regular low dose of oral corticosteroid, but they become increasingly troublesome as higher doses are required. The management of these patients is extremely difficult and the treatment of their asthma and the side effects of corticosteroid therapy consumes much time and money.
Before discussing corticosteroid sparing agents three points need to be made. Firstly, in our experience it is relatively unusual for patients with asthma who are taking inhaled treatment correctly to require more than 5-7-5 mg prednisolone per day for asthma; patients taking more than this should be investigated very carefully. Preventable factors that need to be considered include non-compliance, occupational factors, gastro-oesophageal reflux, specific antigens, and dietary factors. Anxiety about asthma deaths has led to the overuse of corticosteroids by some patients and psychosocial factors and concomitant hyperventilation syndrome can be particularly difficult to disentangle. The second point is that some patients are truly corticosteroid resistant, showing a response to bronchodilators but none to corticosteroids.'2 These patients should not be prescribed corticosteroids. More commonly, patients on oral corticosteroids with severe asthma have some response to corticosteroids although this is relatively small. These are better described as having severe asthma rather than corticosteroid resistance. Lastly, any drug that is effective in asthma -whatever its mechanism of action -will, by definition, have a corticosteroid sparing effect in that less oral corticosteroid will be required to achieve a given improvement in asthma control. This review will not discuss recognised asthma therapies in this category.
Corticosteroid sparing agents Several agents that have been shown to have corticosteroid sparing properties in other conditions have been studied in chronic severe asthma. For this reason we have described them as corticosteroid sparing agents, although some of the studies have looked at the effect of adding, rather than substituting, these agents to existing therapy which has usually, though not always, included corticosteroids (table) . Many of the trials have involved small numbers of patients and patients have not necessarily been receiving optimal doses ofinhaled corticosteroids and bronchodilators. In this review we describe the agents, their presumed mode of action, and the evidence for their efficacy in corticosteroid dependent asthma.
GOLD
Gold has anti-inflammatory properties; it has been shown to inhibit the IgE-mediated release of histamine and LTC4 from basophils and mast cells,3 and guinea pig tracheal smooth muscle incubated in the presence of gold is less responsive to histamine and specific antigen.4 Intramuscular gold is prescribed worldwide for severe rheumatoid arthritis. There have been two studies of intramuscular gold and three of oral gold in asthma.
The first placebo controlled trial of intramuscular gold was carried out by Muranaka et al in 79 asthmatic patients.5 After 30 weeks the gold treated group had fewer symptoms and required less medication; lung function was not measured. Seven patients receiving gold withdrew from the study because of dermatitis, stomatitis, or proteinuria. The same authors subsequently reported that, of 14 subjects studied for five years, five had discontinued all asthma medications whereas six had withdrawn because of dermatitis or stomatitis.6
The first study specifically to address the corticosteroid sparing qualities ofintramuscular gold involved 10 corticosteroid dependent asthmatic patients treated with intramuscular gold or placebo for 22 weeks.7 Five of the patients required lower doses of prednisolone whilst receiving gold without deterioration in their lung function. Gold had to be stopped in two patients who developed severe proteinuria.
In the first trial of oral gold 20 corticosteroid dependent asthma patients treated for 20 weeks (22) Open (20) Double blind (26) Double blind (12) Double blind crossover(l2) Double blind (24) groups; the main differences in outcome were that patients on troleandomycin fared less well in that they had lower serum IgG levels, higher fasting blood sugar and serum cholesterol levels, and a greater reduction in bone mineral density. This study supports the suggestion that any beneficial effects of troleandomycin in corticosteroid dependent asthma relate to reduced metabolism of methylprednisolone. Similar findings were reported in a recent open clinical trial of 14 asthmatic patients who had been on oral corticosteroids for at least six months. When treated with troleandomycin and methylprednisolone for 13 months there was some evidence of benefit in asthma control but this was associated with a reduction in bone mineral density and an increase in plasma glucose concentration.54 In all the troleandomycin studies patients have been taking methylprednisolone and it is still not clear whether all the effects of troleandomycin are due to inhibition of methylprednisolone metabolism.
AZATHIOPRINE
Azathioprine, an antimetabolite, is incorporated into intracellular DNA to prevent cell division. The exact mechanism of its immunosuppressive action is not certain but it is known to suppress the cell-mediated immune response.55 It is used to prevent rejection following organ transplantation and is prescribed for patients with severe rheumatoid arthritis and several other autoimmune disorders. Surprisingly, it has only been studied in asthma in one short and fairly small crossover trial.56 Twenty patients with corticosteroid dependent asthma were randomised to receive placebo or azathioprine, 2 mg/kg or 5 mg/kg/day for three and four weeks respectively, whilst corticosteroid dose was held constant. There was no improvement in symptoms or lung function with azathioprine despite the high doses. Mild dyspepsia was experienced by a few patients and there was a fall in circulating neutrophil count on the higher dose of azathioprine.
INTRAVENOUSLY ADMINISTERED IMMUNOGLOBULIN
Intravenously administered immunoglobulin has immunomodulatory activity and has been shown to inhibit antigen presentation and T and B cell interactions in the immune response. It is efficacious in various immunodeficiency disorders such as idiopathic thrombocytopenic purpura, and has been used to reduce the inflammatory response in systemic juvenile rheumatoid arthritis, Kawasaki There is more convincing evidence of benefit from cyclosporin A, gold, and methotrexate. Cyclosporin A showed efficacy in corticosteroid dependent asthma and its corticosteroid sparing effect has recently been assessed. The trials involving intramuscular and oral gold are encouraging although some are small and of short duration. Methotrexate showed benefit in four of seven studies including the larger and one of the longer studies in asthma. There is some evidence that the benefit of low dose methotrexate therapy in patients with rheumatoid arthritis wanes after 4-6 months, though this was not the case in the positive study of 24 weeks which showed benefit.28
Ifcyclosporin A, gold, and methotrexate have corticosteroid sparing activity, how effective are they? When corticosteroid sparing studies have been carried out the reduction in mean prednisolone dose in the short term has been fairly low, with a range of 0-9 5 mg/day for methotrexate and 0-5 mg/day for gold. The important question is whether this improvement is maintained and, if so, how the side effects of the new drugs over many years compare with the reduction in side effects expected from this reduction in prednisolone dose (0-1O mg) over the same period. Side effects ofgold (stomatitis, dermatitis, and proteinuria) have necessitated treatment being stopped in up to 20% of patients.7 Side effects of methotrexate include hepatic dysfunction (up to 40% in one study29), opportunistic infections such as Pneumocystis carinii,58-62 pulmonary cryptococcosis,63 and nocardiosis,64 and, rarely, pulmonary fibrosis. The latter two are ofparticular concern in patients with asthma since the symptoms may be confused with deteriorating asthma. Treatment with cyclosporin A causes hypertrichosis, hypertension, and renal damage in a proportion of patients. Equating benefit and side effects is further complicated by the fact that both are likely to be a function of log dose rather than dose and the effect ofreducing the dose of prednisolone from 25 to 20 mg may be considerably less than the effect of reducing the dose from 10 to 5 mg per day.
Side effects clearly vary between patients and, for an individual patient, a corticosteroid sparing drug is worthwhile if it is effective and has no important side effects. For others the reverse will be true. Some of the potential side effects can be monitored (blood pressure, white cell count) but others such as opportunistic infections can occur rapidly and may on occasions be fatal. If gold, methotrexate, and cyclosporin A are given to patients with asthma they need appropriate monitoring. The drugs should only be continued if they are beneficial with no important side effects.
A further point that emerges from these studies is that pharmacokinetic data on interactions between some ofthe agents under investigation and concomitant medications that may also be prescribed are very limited. It is possible that some of the agents are acting by affecting the metabolism ofother drugs such as theophylline.
Many of the studies discussed in this review include small numbers of patients and are of relatively short duration. If corticosteroid sparing drugs have a role in the treatment of asthma they need to be effective long term and more information is needed about their side effects over years rather than months. Large multicentre trials are probably needed since the number of patients for whom such a study is appropriate is fairly small. Current management of these patients is unsatisfactory and finding a safer alternative to oral prednisolone should be an important priority.
